Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Stamp

Showing results (151-160 of 323) with videos related to

Pageof 33
Sort By:
British Journal of Clinical Pharmacology|July 13, 2013
Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell typesJulia Korell, Stephen B Duffull, Judith M Dalrymple, et al.
Arthritis Research & Therapy|December 23, 2017
The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trialLisa K Stamp, Peter T Chapman, Murray Barclay, et al.
Rheumatology (Oxford, England)|August 15, 2018
Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trialLisa K Stamp, Peter T Chapman, Murray Barclay, et al.
Arthritis and Rheumatism|August 1, 2009
Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatmentLisa K Stamp, John L O'Donnell, Peter T Chapman, et al.
Arthritis and Rheumatism|April 11, 2012
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinolLisa K Stamp, William J Taylor, Peter B Jones, et al.
Clinical Pharmacology and Therapeutics|July 29, 2011
Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate levelL K Stamp, M L Barclay, J L O'Donnell, et al.
The Journal of Rheumatology|October 4, 2011
Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritisLisa K Stamp, Murray L Barclay, John L O'Donnell, et al.
Clinical Pharmacokinetics|March 14, 2013
A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cellsJulia Korell, Lisa K Stamp, Murray L Barclay, et al.
Drug Metabolism and Pharmacokinetics|October 3, 2018
ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinolLisa K Stamp, Mary Wallace, Rebecca L Roberts, et al.
Annals of the Rheumatic Diseases|August 24, 2017
Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension studyLisa K Stamp, Peter T Chapman, Murray Barclay, et al.
Pageof 33

Showing results (151-160 of 323) with videos related to

Sort By:
Pageof 33
British Journal of Clinical Pharmacology|July 13, 2013
Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell typesJulia Korell, Stephen B Duffull, Judith M Dalrymple, et al.
Arthritis Research & Therapy|December 23, 2017
The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trialLisa K Stamp, Peter T Chapman, Murray Barclay, et al.
Rheumatology (Oxford, England)|August 15, 2018
Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trialLisa K Stamp, Peter T Chapman, Murray Barclay, et al.
Arthritis and Rheumatism|August 1, 2009
Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatmentLisa K Stamp, John L O'Donnell, Peter T Chapman, et al.
Arthritis and Rheumatism|April 11, 2012
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinolLisa K Stamp, William J Taylor, Peter B Jones, et al.
Clinical Pharmacology and Therapeutics|July 29, 2011
Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate levelL K Stamp, M L Barclay, J L O'Donnell, et al.
The Journal of Rheumatology|October 4, 2011
Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritisLisa K Stamp, Murray L Barclay, John L O'Donnell, et al.
Clinical Pharmacokinetics|March 14, 2013
A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cellsJulia Korell, Lisa K Stamp, Murray L Barclay, et al.
Drug Metabolism and Pharmacokinetics|October 3, 2018
ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinolLisa K Stamp, Mary Wallace, Rebecca L Roberts, et al.
Annals of the Rheumatic Diseases|August 24, 2017
Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension studyLisa K Stamp, Peter T Chapman, Murray Barclay, et al.
Pageof 33